Pano Therapeutics ^Company

Pano is a platform biotech venture focused on the clinical development of patented small molecule drugs targeting mitochondrial ion channels addressing a constellation of complex disease states. Pano has identified new classes of compounds with improved access and higher potency targeting the same mitochondrial MOA as Metformin, for which it is initially advancing two main programs: 1. A Natural Compound Formulation program currently in preclinical development stage initially focused on cardiometabolic indications that are characterized by chronic therapeutic intervention, as well as select cancer indications. Pano aims to file its initial IND for this program in 2021; 2. A synthetic compound / NME program currently in the pre-clinical development stage initially focused on development of therapeutics for indications that are characterized by acute therapeutic intervention, initially select cancer indications